Svenska

Varför erbjuds inte svenska prostatacancerpatienter de hjälpmedel som finns tillgängliga för att minska trycket på vården och samtidigt höja patientsäkerheten och livskvaliteten för drabbade?

Non-regulatory pressrelease

I det senaste numret av Dagens Medicin (20 mars 2019) noteras återigen att det är svårt att korta köerna i prostatacancervården. Detta visade ju även Cancerfondens nyligen publicerade rapport som visade att ingen region i Sverige idag uppnår målet att en prostatacancerpatient ska bli opererad inom 61 dagar. Den strida ström av negativa nyheter som…

Läs mer

English

Prostatype Genomics strengthens market organization

Non-regulatory pressrelease

-Recruits Communications Director from Novartis

Read more

Prostatype Genomics AB has completed a directed share issue of approximately SEK 24.7 million

Regulatory pressrelease

Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that the Company has completed a directed share issue of approximately SEK 24.7 million in accordance with the intention communicated to the market through a press release yesterday, August 26[th], 2021.

Read more

Prostatype Genomics AB intends to carry out a directed share issue of approximately SEK 24 million

Regulatory pressrelease

- Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that the Company intends to carry out a directed share issue of approximately SEK 24 million to Swedish and international investors. The Company has assigned Sedermera Fondkommission to act as bookrunner in connection with the directed share issue. The capital raise is intended to finance…

Read more

Prostatype Genomics AB enters into cooperation with leading actor in the prostate cancer area

Regulatory pressrelease

– Agreement on marketing and R&D cooperation enhancing market position short- and long-term

Read more

Prostatype ® P-score and prognostic evaluation in Prostate cancer to be presented at the largest Urology meeting in the world

Non-regulatory pressrelease

-Results of the study from Skåne University Hospital selected to present during American Urology Congress 2021

Read more

Prostatype Genomics appoints Eligen Diagnostica Sociedad Limitada and BioPortugal Quimico Farmacêutica Lda. to distribute the Prostatype ® Prostate gene test in Spain and Portugal

Regulatory pressrelease

- An important step taken in the commercialization of Prostatype®

Read more

Prostatype Genomics presents Interim Report for the period 1 April to 30 June 2021

Regulatory pressrelease

- Prostatype Genomics presents Quarterly report for the second quarter of 2021. The Report is available on the Company's home page.

Read more

Prostatype Genomics signs agreement with Cambridge Clinical Laboratories, CCL

Regulatory pressrelease

-Prostatype® prostate cancer test made available for patients in UK & Ireland

Read more

Results from Groundbreaking Study with Prostatype® Additionally Strengthens the Clinical Benefits

Regulatory pressrelease

Prostatype Genomics continues to deliver on the overall strategy of the Company and the previously communicated milestones. One of two main focus areas is the continued strengthening of the scientific footprint through scientific studies performed by internationally recognized clinics and research institutions. An additional milestone in the development of the Company has now been achieved…

Read more

Prostatype Genomics appoints Sedermera Fondkommission as liquidity provider for the company´s share

Regulatory pressrelease

The liquidity providing commences on June 17, 2021

Read more

Communique from annual general meeting in prostatype genomics AB (publ)

Regulatory pressrelease

The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the “Company”) was held on June 16, 2021 by postal voting whereby the shareholders resolved on the following matters.

Read more

Prostatype Genomics strengthens customer offer and logistics with switch to new contract manufacturer Minerva Biolabs

Non-regulatory pressrelease

Prostatype® will be offered as a dry powder solution

Read more

Prostatype Genomics presents Interim Report for the period 1 January to 31 March 2021

Regulatory pressrelease

Prostatype Genomics presents Quarterly report for the first quarter of 2021. The Report is available on the Company's home page.

Read more

Notice of Annual General Meeting in Prostatype Genomics AB and invitation to virtual information meeting

Regulatory pressrelease

NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

Read more

Prostatype Genomics publishes Annual Report for 2019/20

Regulatory pressrelease

Prostatype Genomics AB today publishes the Annual Report for the extended financial year of July 2019 to December 2020. The Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com

Read more

Prostatype Genomics announces strong results for Prostatype® in first step validation study of Asian population

Regulatory pressrelease

Prostatype Genomics AB (”Prostatype  Genomics” or ”The Company”) is releasing  data from the first step of the previously communicated and ongoing validation study in Taiwan.

Read more

Prostatype Genomics strengthens its product offering by launching P-score Web Service (PWS)

Regulatory pressrelease

Prostatype Genomics AB (”Prostatype  Genomics” or ”The Company”) is today launching P-score Web Service (”PWS”), a web based solution for the calculation of the Company’s patented method Prostatype Score, P-score.

Read more

Prostatype Genomics presents Quarterly- & Year End Report

Regulatory pressrelease

Prostatype Genomics AB has today published its quarterly report for the sixth quarter of the extended financial year comprising the period from 1 October 2020 to 31 December 2020, and the year end report for the extended financial year. The extended financial year covers the period from 1 July 2019 to 31 December 2020. The…

Read more